Trending...
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- GitKraken Introduces GitLens 19, Bringing Human and AI Workflows Together in One Workbench
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.
SAN DIEGO - PennZone -- About John Burd, PhD:
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
- Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
- Independent Colbert Packaging Thrives Amid Industrywide Consolidation
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
- Slotozilla Reports Strong Growth in Q2 2026
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Source: Beneficience.com Legacy PR
0 Comments
Latest on The PennZone
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
- Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
- Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World
- DuraFast Label Company Launches Seiko SLP850 2" Thermal Printer with Free Label Promotion
- Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
- Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
- Philly Tailgates Announces Full 2026 Eagles Season Schedule, Opening With Back-to-back Events
- The Golden Jazz Fest Shuttle Returns for 2026
- KeysCaribbean Resorts Offer Savings On Vacations Through Aug. 31, Preview Exceptional Select Fall Rates of Less Than $200/Night
- Fit Body Boot Camp Launches Nationwide 'Fit Body Forever' Workshops to Help Adults 60+ Rebuild Strength and Prevent Falls
- Canadian Aerospace Defence Talent Expo (CADTE) Launches National TalentThread Initiative to Strengthen Canada's Future Workforce
- 5.6 Million EUR in Q1 Project Awards for Integrated IoT Solutions / Data Analytics Subsidiary of Smart City Developer: Affluence (Stock Symbol: AFFU)
- Merger Advancement For Embodied AI Co in Robotic Systems Serving High Value Hospitality, Gaming & Real Estate Sectors: MBody AI Corp. (NAS DAQ: MBAI)
- Hollywood In Pixels Announces Honorees for The 9th Silver PIXel Awards
- New Research Finds a Good Deal Is All It Takes to Get Americans Booking a Last-Minute Vacation — and Most Already Have One on Their Mind
- GitKraken Introduces GitLens 19, Bringing Human and AI Workflows Together in One Workbench
- LĪNA Universal Balm Nominated for "Best Clean Skincare Product" at CertClean Beauty Awards
- Bronze Stevie Award Recognizes Satyadhar Joshi for AI Research and Public Policy Engagement
- synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool